25 Posts You Should Not Miss From ESMOGI24!
ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Our team at OncoDaily has compiled a list of 25 posts from this conference that you should not miss!
ESMOGI24: Growing evidence supports the use of ctDNA as a biomarker in colon cancer. Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication.
Great discussion by Juan O’ Connor in the mini-oral session ESMOGI24. Putting NEST-1 and ECOG study into perspective.
Also for highlighting our TARZAN trial with atezo/bev in rectal cancer for organ preservation (42% OP rate in 38 pMMR patients).
New data from the NEST clinical trial was just presented at ESMO – European Society for Medical Oncology’s ESMOGI24. The results demonstrated significant tumor reductions in MSS colon cancer patients treated with botensilimab/balstilimab in the neoadjuvant setting. Learn more here.
This is the football/oncology crossover I’m here for, Chiara Cremolini!
I agree KEYNOTE-177 v CheckMate 8HW is fraught with the pitfalls of cross-trial comparison (FWIW, I still favor pembro alone unless I really need a quick response making anti-CTLA4 more worthwhile).
How to advise patients with poor response on interim MRI after induction CRT in TNT?
Among 40 patients in our series 2015-2021 with interim mrTRG4:
- 2 sustained cCR after consolidation chemo
- Of 38 TME, 10 (26%) had pCR
- Recommend completion of TNT
NEST Trial responses to date. What’s particularly of note is the deepening of the responses with longer time to brew. The pattern and lack of recurrence speaks to curative potential of immunotherapy for both MSS and MSI-High tumors.
Great educational session at ESMOGI24 -about GEP-NETS. But above all, Rachel Riechelmann
always strives to have new answers on practical patients issues, such as how to avoid everolimus dose-related toxicity. Looking forward to this trial!
Fantastic Keynote Lecture on targeting KRAS in Gastrointestinal Cancers in ESMOGI24 by Ryan Corcoran. 90% of PDAC are KRAS mutant.
“ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with the gut microbiome, lessons learned about the importance of its composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care.
Being able to identify the patients with poor gut microbiota composition provides clinicians with the opportunity to manipulate the microbiome and thereby potentially enhance their subsequent response to immunotherapy.
Read the ESMO Daily Reporter article to explore how advancing Microbiome Research is reshaping CRC treatment.”
Germline mutations are common in non-familial pancreatic cancer.
Lifetime pancreatic cancer risk by gene
Screening in high-risk individuals?
No standard method .
Imaging may be used alternatingly, Ca19-9?
Great summary of biliary tract cancer and gene target therapy at ESMOGI24.
The new NSCLC by Arndt Vogel but what will it take to get the targeted therapies into the 1st line setting like driver oncogene addicted NSCLC?
Is chemoIO is less efficacious in patients with driver alterations?
Fantastic discussion on localized biliary cancers – surgical and therapeutic approaches. Multidisciplinary management is key.
One of highlights of the ESMOGI24 for YOs.
- Opportunity for networking and mentorship
- Listen the journeys of giants of the field
- Discuss patient management with real-world cases”
ESMOGI24 nivo/rego plus short course RT promising in MSS rectal cancer? REGINA trial meets stage I endpoint and moves to Stage II with low dose regorafaenib.
ESMOGI24: How has treatment of Liver Cancer improved in the past decade?
- Novel agents: Checkpoint inhibitors represented a paramount improvement in the availability of effective therapies, particularly when used in combination regimens or conjunction with some locoregional approaches.
- Rethinking of accepted treatment concepts: The activity of immunotherapy combinations is prompting a rethinking of the place of systemic therapy within traditional strategies and is highlighting the importance of a multidisciplinary approach to treatment.
- New roles for older treatment modalities: Radiotherapy has the potential to synergise with systemic immunotherapy, and also to overcome resistance to immune treatments, making the combination of radiotherapy and immunotherapy a particularly powerful tool.
Read the ESMO Daily Reporter to dive into the journey of liver cancer treatment and take a glimpse into future opportunities and challenges.
Mitazalimab (anti-CD40) added to FOLFIRINOX: impressive results. The next step for the treatment of metastatic pancreatic cancer? Great talk given at ESMOGI24 Teresa Macarulla.
Our multicenter study found that renal dysfunction, age and Olmesartan increase risk of severe diarrhea in colorectal cancer patients treated with CAPOX.
According to the latest results presented at ESMOGI24, liver transplantation alongside chemotherapy shows remarkable results in a highly selected patient population with unresectable colorectal liver metastases.
The TRANSMET trial reveals that this approach could quadruple the 5-year overall survival rate compared to chemotherapy alone.
Read the ESMO Daily Reporter to learn more about these findings in colorectal cancer.
Sequential treatment of advanced HCC, review by Ghassan Abou-Alfa
- checkpoint inhibitors and combination of are the mainstay therapy for advanced HCC
- response checkpoint is dependent on the tumor immune microenvironment
- access to treatments remains challenging worldwide
ESMOGI24 take-home messages: Hepatopancreaticobiliary cancer at ESMOGI24 by Teresa Macarulla.
- HCC: Blood-based AI HCC surveillance, IO , ctDNA
- PDAC: KRASi, CD40, biomarkers…
- BTC: TOPAZ 3 year update, molecular profiling
KN585 OS (noting EFS/trial status negative despite 20m improvement). OS benefit 6% at 5 years. FLOT (v CF) backbone did better (cis poor PD1 partner), but only 20% cohort, clear benefit CPS >10/MSI-H. Appealing option; may solidify with MATTERHORN survival (100% FLOT).
The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest that the current treatment standard for resectable gastric/gastro-oesophageal junction cancers should remain unchanged. Event-free survival was not significantly improved with pembrolizumab plus chemotherapy compared to placebo plus chemotherapy or placebo plus FLOT.
According to Elizabeth Smyth however, the increase in the pathological complete response rate seen with the addition of pembrolizumab suggests it may improve response to chemotherapy in at least some patients.
To learn more about this topic, read the ESMO Daily Reporter article.
ESMOGI24 is coming to an end. Wrap up and future directions for CRC:
- liver transplant
- molecularly targeted agents
- immunotherapy
- quality of life
Amazing ESMO conference on GI tumors- headed back to Houston with many new ideas. Great rectal cancer talk highlighting oddity of NCCN recommendation for adjuvant chemo after pre op CRT. In 2024 this decision needs to be guided by ctDNA.
ESMOGI24 is coming to an end… an excellent first time! Science, networking and fun… highly recommendable! Now ready to bring energy and motivation to our daily life and patients.
